Clinical Trial ProgressThe first trial site in the company's pivotal Phase 3 OVATION 3 study has been activated, with additional sites expected to follow, indicating robust study progress.
FDA AlignmentImunon has full FDA alignment for its OVATION 3 trial, which is a positive development for advancing their study and potentially accelerating the approval process.
Regulatory ApprovalIMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity, potentially expediting approval processes.
Vaccine DevelopmentThe IMNN-101 DNA plasmid vaccine shows durable immune responses with heightened responses in higher dose cohorts, demonstrating promise as a seasonal COVID-19 vaccine.